07:00 , Aug 13, 2012 |  BioCentury  |  Emerging Company Profile

Wilson Therapeutics: Clearing copper

Wilson Therapeutics AB is repurposing a metal-binding cancer compound into a therapy for Wilson's disease, a rare hereditary condition that leads to accumulation of toxic levels of copper. The compound, Decuprate, may be a safer...
07:00 , Mar 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Plasminogen activator, urokinase receptor (PLAUR; UPAR) In vitro and mouse studies suggest that plasmin could help improve stem cell...
07:00 , Jul 17, 2008 |  BC Innovations  |  Targets & Mechanisms

Cancer's Long-distance Plan

Researchers at the Massachusetts Institute of Technology have uncovered a new role for the endocrine factor osteopontin as a 'long-distance' modulator of tumor growth. Researchers polled by SciBX felt that the findings not only opened...
07:00 , May 29, 2008 |  BC Innovations  |  Cover Story

Cancer Grows on SOD1

A report in the Proceedings of the National Academy of Sciences shows how superoxide dismutase 1 acts as a master regulatory switch for kinase phosphorylation in angiogenesis and cell proliferation, making it a potential target...
07:00 , May 29, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Superoxide dismutase 1 (SOD1); MAP kinase ERK-1; MAP kinase ERK-2 Studies in cell culture suggest that antagonizing SOD1 could...
07:00 , May 29, 2008 |  BC Innovations  |  Targets & Mechanisms

Swell Effect on Glioma

Gliomas, unlike most other tumor types, grow and expand by killing off surrounding tissue, causing neurodegeneration and edema. Chemotherapy and radiotherapy attack the tumor itself, but do not address these two other effects of the...
07:00 , May 8, 2008 |  BC Innovations  |  Targets & Mechanisms

D-coupling Multiple Myeloma's Codependents

Three years ago researchers at the Mayo Clinic Arizona reported that most types of multiple myeloma overexpress cyclin D1 and/or cyclin D2. 1 Following on that earlier work, a new research team at the clinic...
07:00 , Apr 10, 2008 |  BC Innovations  |  Cover Story

Metastasis, Interrupted

Two studies have clarified the roles of two different proteins in metastasis, suggesting potential new therapeutic strategies to treat cancer. One study proposes agonizing the membrane protein CD151 to prevent cancer cells from mobilizing at...
08:00 , Feb 7, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Superoxide dismutase (SOD1) Studies in mice show that antagonizing or blocking expression of mutant SOD1 in astrocytes...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Company News

Attenuon, Xoma Ltd. deal

XOMA will use its Human Engineering technology to humanize Attenuon's lead murine antibody targeting the urokinase-type plasminogen activator ( uPA ) system to treat cancer. XOMA will receive an upfront fee and is eligible for...